Opiate addiction - current trends and treatment options
DOI:
https://doi.org/10.18203/2320-6012.ijrms20161911Keywords:
Opiates, Prescription, Addiction, Methadone, NaltrexoneAbstract
Opioids are widely used drugs for treatment of pain and related disorders. Opiate addiction is a major public health concern in the United States causing significant increase in healthcare expenditure. They produce euphoria and sense of well-being which makes them addictive to some people. Used in higher doses they can lead to cardiac or respiratory compromise. They also impair cognition leading to impaired decision making. Opioids exert their effects by acting on three different types of receptors mu, delta, and kappa located on neuronal cell membranes causing inhibition of neurotransmitter release. Prolonged use of these drugs can lead to physical dependence causing withdrawal symptoms if a person stops using them. Commonly used medications to treat opiate addiction are methadone, LAAM (longer acting derivative of methadone), buprenorphine, and naltrexone.
References
UNODC. World drug report 2011. 2011. United Nations Publication (Sales No. E.11.XI.10).
Blum K, Thomas JH Chen, John Bailey, Abdulla Bowirrat, John Femino, Amanda LC Chen. Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential? Mol Neurobiol. 2011;44(3):250-68.
Centers for disease control and prevention. Vital signs: Overdoses of prescription opioid pain relievers - United States, 1998-2008. MMRW. 2011;60:1487-92.
Substance abuse and mental health services administration. Rockville, MD: Office of Applied Studies; 2011. Results from the 2010 National Survey on Drug Use and Health: summary of national findings. DHHS Publication; SMA 11-4658. NSDUH Series H-41.
Substance Abuse and Mental Health Services Administration. Treatment episode data set. 2011.
Jentsch JD, Taylor JR. Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behaviour by reward-related stimuli. Psychopharmacology. 1999;146:373-90.
Volkow ND, Fowler JS. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cereb. Cortex. 2000;10:318-25.
Bechara A. Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive perspective. Nature Neurosci. 2005;8:1458-63.
Ornstein TJ. Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology. 2000;23:113-26.
Kalinichev M, Easterling KW, Holtzman SG. Long-lasting changes in morphine-induced locomotor sensitization and tolerance in long-evans mother rats as a result of periodic postpartum separation from the litter: a novel model of increased vulnerability to drug abuse? Neuropsychopharmacology. 2003;28:317-28.
Brook JS, Brook DW, Zhang C, Cohen P. Pathways from adolescent parent-child conflict to substance use disorders in the fourth decade of life. Am J Addict. 2009;18:235-42.
Tsuang MT, Lyons MJ, Meyer JM. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry. 1998;55:967-72.
Mills KL, Teesson M, Ross J, Peters L. Trauma, PTSD, and substance use disorders: findings from the Australian National Survey of Mental Health and Well-Being. Am J Psychiatry. 2006;163:652-8.
Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev. 2005;57(1):1-26.
Yuferov V, Levran O, Proudnikov D, Nielsen DA, Kreek MJ. Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci. 2010;1187:184-207.
16. Levran O, Yuferov V, Kreek MJ. The genetics of the opioid system and specific drug addictions. Hum Genet. 2012;131(6):823-42.
Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci. USA. 1988;85(14):5274-8.
Maisonneuve IM, Kreek MJ. Acute tolerance to the dopamine response induced by a binge pattern of cocaine administration in male rats: an in vivo microdialysis study. J Pharmacol Exp Ther. 1994;268(2):916-21.
Pettit HO, Ettenberg A, Bloom FE, Koob GF. Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. Psychopharmacology (Berl). 1984;84(2):167-73.
Tsukada H, et al. Effects of binge pattern cocaine administration on dopamine D1 and D2 receptors in the rat brain: an in vivo study using positron emission tomography. J Neurosci. 1996;16(23):7670-7.
Spangler R, Zhou Y, Maggos CE, Zlobin A, Ho A, Kreek MJ. Dopamine antagonist and binge cocaine effects on rat opioid and dopamine transporter mRNAs. Neuroreport. 1996;7(13):2196-200.
Volkow ND, Fowler JS, Wolf AP, Schlyer D, Shiue CY, Alpert R,. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry. 1990;147(6):719-24.
Zhou Y, Leri F, Cummins E, Hoeschele M, Kreek MJ. Involvement of arginine vasopressin and V1b receptor in heroin withdrawal and heroin seeking precipitated by stress and by heroin. Neuropsycho- pharmacology. 2008;33(2):226-36.
Zhou Y, Bendor J, Hofmann L, Randesi M, Ho A, Kreek MJ. Mu opioid receptor and orexin/hypocre- tin mRNA levels in the lateral hypothalamus and striatum are enhanced by morphine withdrawal. J Endocrinol. 2006;191(1):137-45.
Kreek MJ, Levran O, Reed B, Schlussman SD, Zhou Y, Butelman ER. Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. Clin Invest. 2012;122(10):3387-93
Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci. 1992;12:483-88.
Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F. Addiction: beyond dopamine reward circuitry. Proceedings of the National Academy of Sciences. 2011;108:15037-42.
Ahmadi J, Ahmadi K, Ohaeri J. Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study. Eur J Clin Chem Clin. 2003;33:824-9.
Bonhomme J, Shim RS, Gooden R, Tyus D, Rust G. Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options. J Natl Med Assoc. 2012;104(0):342-50.
Schottenfeld RS, Chawarski MC, Pakes JR, Pantalon MV, Carroll KM, Kosten TR. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatr. 2005;162(2):340.
Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. science & practice perspectives. 2002;1(1):13-20.
Strang J, Hall W, Hickman M, Bird SM. Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): analyses using OD4 index in England and Scotland. BMJ. 2010;341:c4851.
Bentley KW, Hardy DG. Novel analgesics and molecular rearrangements in the morphine-thebaine group 3. Alcohols of the 6,14-endoethenotetrahydrooripavine series and derived analogs of N- allylnormorphine and norcodeine. J Am Chem Soc. 1967;89:3281-92.
Ling W, Casadonte P, Bigelow G. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA. 2010;304:1576-83.
Kosten TR, Morgan C, Kreek MJ. Beta endorphin levels during heroin, methadone, buprenorphine, and naloxone challenges: preliminary findings. Biol Psychiatry. 1992;32:523-8.
Weerts EM, Kim YK, Wand GS. Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol- dependent subjects. Neuropsychopharmacology. 2008;33:653-65.
Pfohl DN, Allen JI, Atkinson RL, Knopman DS, Malcolm RJ, Mitchell JE. Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage. NIDA Res Monogr. 1986; 67:66-72.
